BNP Paribas downgraded DSM-Firmenich stock to Neutral

Published on 10/08/2026 at 12:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BNP Paribas set a EUR 100.00 target on October 2, 2026. DSM-Firmenich stock costs EUR 97.33 on October 8, 2026 after EUR 100.25, below its EUR 100.50 high.

Börsen-Editorialfoto vom Trading-Floor mit Charts und Molekülgrafiken — dsm-firmenich AG (ISIN CH1216478797) notiert an der SIX, als Editorial-Szene vom Börsen-Trading-Floor mit Charts dargestellt, Illustration mit AI erstellt.

DSM-Firmenich (ISIN CH1216478797) was trading at EUR 97.33 at Lang & Schwarz on October 8, 2026 at 12:16 p.m. CEST, down 2.91 percent versus the prior close of EUR 100.25. According to Markets Insider on October 2, 2026, BNP Paribas analyst Nicola Tang downgraded the company from Outperform to Neutral and set a EUR 100.00 price target. The stock therefore sits 2.67 percent below that target, leaving the analyst action cautious rather than outright bearish.

Neutral rating meets a EUR 100 target

The downgrade matters because the target is only EUR 2.67 above the Lang & Schwarz price. BNP Paribas did not remove the valuation anchor, but its Neutral stance places the current quote close to the bank's stated target rather than pointing to a large rerating.

The external view also contrasts with higher targets listed in the same recent market coverage. MarketWatch reported a Citi target of EUR 111.00, while the BNP Paribas target stands at EUR 100.00, creating a EUR 11.00 spread between the two published views.

Half-year growth came with cash pressure

In a September 27, 2026 analysis of the July 30 half-year results, De Belegger reported continuing revenue of EUR 4.66 billion for the first half of 2026. Comparable revenue growth was 5.00 percent in the first half and 6.00 percent in the second quarter.

Adjusted earnings before interest, taxes, depreciation and amortization reached EUR 900.0 million in the first half of 2026, producing a 19.30 percent margin. Comparable adjusted EBITDA grew 7.00 percent, although gross cash conversion was 7.00 percent against full-year guidance of 11.00 percent to 12.00 percent. That gap makes cash generation a key test alongside operating growth.

Buyback reduces the share base

A company release published by FinanzNachrichten.de on October 1, 2026 said DSM-Firmenich had completed its EUR 540.00 million share repurchase. The program bought 7,169,147 shares at an average EUR 75.32 per share, and 6,488,446 shares are intended for cancellation by the end of the first quarter of 2027.

The capital reduction is a concrete support for per-share value, but it does not remove the execution issue highlighted by the cash-conversion figures. The market capitalization was EUR 24.1 billion on October 8, 2026, while the 52-week range was EUR 55.22 to EUR 100.50.

Stock remains below its yearly high

At EUR 97.33, DSM-Firmenich stock was 3.15 percent below its EUR 100.50 52-week high on October 8, 2026. The combination of a Neutral rating at EUR 100.00, higher competing targets and the cash-conversion gap leaves operating delivery as the central valuation question.

The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.